bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

bluebird bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaborations with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc Key Recent Developments

Mar 26,2020 bluebird bio provides assessment of impact of COVID-19, update on business operations and clinical program development
Feb 18,2020 bluebird bio reports fourth quarter and full year 2019 financial results and highlights operational progress
Oct 31,2019 bluebird bio reports third quarter 2019 financial results and highlights operational progress
Oct 23,2019 bluebird bio announces transition of Chief Strategy Officer Jeffrey T. Walsh

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
bluebird bio Inc - Key Facts
bluebird bio Inc - Key Employees
bluebird bio Inc - Key Employee Biographies
bluebird bio Inc - Major Products and Services
bluebird bio Inc - History
bluebird bio Inc - Company Statement
bluebird bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
bluebird bio Inc - Business Description
bluebird bio Inc - Corporate Strategy
bluebird bio Inc - SWOT Analysis
SWOT Analysis - Overview
bluebird bio Inc - Strengths
bluebird bio Inc - Weaknesses
bluebird bio Inc - Opportunities
bluebird bio Inc - Threats
bluebird bio Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
bluebird bio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 26, 2020: bluebird bio provides assessment of impact of COVID-19, update on business operations and clinical program development
Feb 18, 2020: bluebird bio reports fourth quarter and full year 2019 financial results and highlights operational progress
Oct 31, 2019: bluebird bio reports third quarter 2019 financial results and highlights operational progress
Oct 23, 2019: bluebird bio announces transition of Chief Strategy Officer Jeffrey T. Walsh
Oct 10, 2019: Novo Nordisk and bluebird bio to develop genetic disease therapies
Oct 09, 2019: bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates for haemophilia and other severe genetic diseases
Sep 27, 2019: bluebird bio appoints William R. Sellers, M.D. to Board of Directors
Aug 01, 2019: bluebird bio reports second quarter 2019 financial results and highlights operational progress
May 09, 2019: bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies
May 02, 2019: bluebird bio reports first quarter 2019 financial results and highlights operational progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


bluebird bio Inc, Key Facts
bluebird bio Inc, Key Employees
bluebird bio Inc, Key Employee Biographies
bluebird bio Inc, Major Products and Services
bluebird bio Inc, History
bluebird bio Inc, Other Locations
bluebird bio Inc, Subsidiaries
bluebird bio Inc, Key Competitors
bluebird bio Inc, Ratios based on current share price
bluebird bio Inc, Annual Ratios
bluebird bio Inc, Annual Ratios (Cont...1)
bluebird bio Inc, Interim Ratios
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
bluebird bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


bluebird bio Inc, Performance Chart (2015 - 2019)
bluebird bio Inc, Ratio Charts
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

USD 125 View Report

bluebird bio Inc Strategic Analysis Review- bluebird bio Inc SWOT, Outlook, Operations and Financial Profile

bluebird bio Inc Company Profile provides strategic analysis of bluebird bio Inc Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth

USD 200 View Report

Access Bio Inc (950130) - Product Pipeline Analysis, 2021 Update

Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic

USD 750 View Report

Access Bio Inc (950130) - Product Pipeline Analysis, 2021 Update

Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available